Summary & Overview
HCPCS J9360: Vinblastine Sulfate Injection, 1 mg
HCPCS Level II code J9360 denotes a 1 mg unit of vinblastine sulfate administered as an injectable chemotherapeutic agent. Vinblastine is used in multiple oncology protocols; accurate coding of drug units is critical for clinical documentation, billing accuracy, and national drug utilization reporting. Given the high-cost and high-complexity nature of chemotherapy drug billing, correct use of J9360 affects claim processing, reimbursement determinations, and inventory management across care settings.
This analysis covers national payer approaches including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, common billing modifiers, and payer-specific billing practices where available. The publication provides benchmark context for billing and reimbursement, highlights clinical settings where J9360 typically appears, and summarizes policy updates and documentation requirements that influence claim adjudication.
The report is organized to help billing managers, revenue cycle staff, and oncology practice leaders understand coding implications, national payer interactions, and areas where administrative attention is required. Data not available in the input will be noted where appropriate.
Billing Code Overview
HCPCS Level II code J9360 represents injection, vinblastine sulfate, 1 mg, a chemotherapeutic agent administered via parenteral injection. This code describes the drug product and unit strength for vinblastine sulfate used in oncology treatment regimens.
-
Service type: Intravenous or intramuscular chemotherapy drug administration
-
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or outpatient clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing outpatient chemotherapy for a hematologic malignancy such as Hodgkin lymphoma or other vinblastine-sensitive neoplasm. The patient presents to an infusion center or hospital oncology clinic for administration of vinblastine sulfate. Pre-infusion check-in includes verification of diagnosis, review of prior labs (complete blood count, liver function tests), consent confirmation, and allergy review. A chemotherapy-certified nurse prepares the dose using aseptic technique from a vial, drawing the appropriate milligram amount based on the oncologist’s order. The medication is administered intravenously as a bolus or short infusion through a peripheral IV or central venous access device under standard chemotherapy safety protocols. Vital signs and infusion tolerance are monitored during and after administration; supportive medications (antiemetics, hydration) may be provided per protocol. Documentation includes the drug name, strength and quantity in milligrams, lot number, route, site of administration, administering clinician, and any immediate adverse reactions. Billing is submitted using J9360 for vinblastine sulfate, billed per milligram as described, with appropriate modifier(s) added to reflect service circumstances (for example, professional component, discontinued service, or drug wastage).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/unused |